市场调查报告书
商品编码
1152006
尿路癌全球市场规模研究与预测:按癌症类型、治疗类型、分销渠道和地区分析,2022-2029 年Global Urinary Tract Cancer Market Size study & Forecast, by Cancer Type, Treatment Type, and Distribution Channel and Regional Analysis, 2022-2029 |
到 2021 年,全球尿路癌症市场价值约为 20.2 亿美元,预计在 2022-2029 年的预测期内将以超过 18.6% 的健康增长率增长。
泌尿道癌是一种影响尿道、膀胱和肾盂的癌症。尿道癌是一种影响将尿液从膀胱输送到体外的管道的癌症。膀胱癌是指排列在膀胱内壁的称为尿路上皮细胞的健康细胞发生变化并失去控製而形成肿瘤。化学疗法和免疫疗法被用作尿路癌的治疗方法。膀胱癌患病率的增加、私人和政府组织的资金活动增加以及主要市场参与者的战略举措是加速市场增长的主要因素。
根据国际世界癌症研究基金会的数据,到 2020 年,全球将报告约 573,278 例膀胱癌新病例,占所有癌症类型的 3.2%。此外,美国癌症协会估计,到 2022 年,美国将报告大约 81,180 例膀胱癌新病例(大约 61,700 名男性和 19,480 名女性)。大约有 17,100 人死于膀胱癌。此外,在预测期内,新兴国家久坐不动的生活方式的激增和不断增长的医疗基础设施预计将为膀胱癌市场创造有利的增长前景。然而,与尿路癌相关的高昂治疗费用和与处方药相关的副作用将阻碍整个 2022-2029 年预测期内的市场增长。
全球尿路癌症市场研究中考虑的主要区域是亚太地区、北美、欧洲、拉丁美洲和世界其他地区。由于膀胱癌发病率上升和该地区拥有强大的医疗基础设施等因素,北美已成为市场份额的主要地区。另一方面,由于老年人口的增加以及超专科医院、癌症治疗中心等的激增,预计亚太地区在预测期内将显着增长。
本报告中提到的主要市场进入者是:
近期市场动态。
全球尿路癌症市场研究范围。
历史数据: 2019-2020-2021
基准估计年份:2021
预测期:2022-2029
报告的收入预测、公司排名、竞争格局、增长因素、趋势
目标细分癌症类型、治疗类型、分销渠道、地区
区域范围北美、欧洲、亚太地区、拉丁美洲、世界其他地区
购买一份研究覆盖率报告即可免费定制(相当于最多 8 位分析师的工作时间)。添加或更改国家、地区、航段范围*
这项研究的目的是定义近年来各个细分市场和国家的市场规模,并预测他们在未来几年的价值。该报告旨在捕捉被调查国家工业的定性和定量方面的情况。
它还提供了有关关键方面的详细信息,例如将定义市场未来增长的驱动因素和挑战。此外,它还包含供利益相关者投资的微观市场潜在机会,以及对主要参与者的竞争格局和产品供应的深入分析。市场的详细细分和子细分如下所述。
按癌症类型
膀胱癌
尿道癌
输尿管/肾盆腔癌
按治疗类型
化学处理
免疫疗法
按销售渠道
零售店
网上药店
按地区
北美
美国
加拿大
欧洲
英国
德国
法国
西班牙
意大利
欧洲其他地区
亚太地区
中国
印度
日本
澳大利亚
韩国
其他亚太地区
拉丁美洲
巴西
墨西哥
世界其他地区
Global Urinary Tract Cancer Market is valued approximately USD 2.02 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 18.6% over the forecast period 2022-2029. Urinary Tract Cancer is a type of cancer that affects urethra, bladder, and renal pelvic. Urethral cancer affects the tube that carries urine from bladder to outside of the body. Whereas in Bladder Cancer the healthy cells in the bladder lining called as urothelial cells, change, and grow out of control and form a tumor. Chemotherapy, and Immunotherapy are used as treatment procedure for treatment of Urinary Tract Cancer. The increasing prevalence of bladder cancer and growing number of funding activities from private & government organizations as well as strategic initiatives from leading market players are key factors accelerating the market growth.
According to the World Cancer Research Fund International - in 2020, around 573278 new cases of bladder cancer were reported worldwide, representing 3.2% of all cancer type. Moreover, as per American Cancer Society's estimates - in 2022, around 81,180 new cases of bladder cancer (about 61,700 in men and 19,480 in women) reported across the United States. In addition, around 17,100 individuals lost their lives due to bladder Cancer. Also, surge in sedentary lifestyle and rising healthcare infrastructure in emerging regions would create lucrative growth prospectus for the market over the forecast period. However, the high treatment cost associated with Urinary tract cancer and side effects associated with prescribed drugs impede the market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Urinary Tract Cancer Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as Increasing incidences of bladder cancer as well as availability of robust healthcare infrastructure in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising number of geriatric individuals as well as increasing penetration of super specialty hospitals and cancer care centers in the region.
Major market players included in this report are:
Astellas Pharma Inc.
Bristol-Myers Squibb Company
Eli Lily and Company
Endo International plc.
Exelixis, Inc.
GlaxoSmithKline Plc. (GSK)
Merck KGAA
Novartis AG
Pfizer Inc.
Johnson & Johnson
Recent Developments in the Market:
Global Urinary Tract Cancer Market Report Scope:
Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Cancer Type, Treatment Type, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Cancer type
Bladder Cancer
Urethral cancer
Ureteric and Renal Pelvic Cancer
By Treatment Type
Chemotherapy
Immunotherapy
By Distribution Channel
Retail Pharmacy
Online Pharmacy
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable